Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000870 · ClinicalTrials.gov registry record · Early Phase 1
Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
A Early Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01000870 is a Early Phase 1 study that was terminated before completion, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 6 participants.
The verdict
NCT01000870, a Early Phase 1 study, was terminated before completion, sponsored by Institute for Neurodegenerative Disorders.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers.
Interventions
- DRUG MNI-513-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000870
The ClinicalTrials.gov registry entry for NCT01000870 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MNI-513-01 is the first listed.
NCT01000870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01000870 about?
NCT01000870 is a clinical study titled "Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513". The purpose of the study is to evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers.
What is the current status of trial NCT01000870?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2009-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01000870?
The interventions under investigation include: MNI-513-01 (DRUG).
Who is sponsoring clinical trial NCT01000870?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.